Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.93 - $95.25
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.97M
Market Cap
$43.88B
Enterprise Value$40.10B
Total Cash (Recent Filing)$321.20M
Total Debt (Recent Filing)$129.30M
Price to Earnings (P/E)30.3
Beta0.90
Next Earnings
Jul 24, 2025EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding585,755,500
10 Day Avg. Volume5,381,898
30 Day Avg. Volume4,971,709
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda22.11
Forecast
1Y Price Target
$80.25Price Target Upside6.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval of the SAPIEN 3 platform in asymptomatic patients is expected to unlock a large commercial opportunity for Edwards Lifesciences.
Q1 PerformanceEdwards Lifesciences posted better-than-expected TAVR growth, consistent with recent survey data, and continued momentum in TMTT.
Revenue GuidanceManagement raised its FY25 TMTT revenue guidance by ~5% at the midpoint and maintained its FY25 overall company and TAVR revenue guidance ranges.
Bears Say
Competitive PressureContinued weakness in Japan due to lower procedure growth and competitive pressure is a challenge for Edwards Lifesciences.
Hospital Capacity ConstraintsHospital capacity constraints driven by emerging structural heart therapies have negatively impacted US TAVR volumes in recent quarters.
Pricing EnvironmentConcerns exist about the pricing environment for TAVR, as some competitors have been pricing at sizable discounts.
---
Ownership Overview
0.94% Insiders
23.18% Mutual Funds
1.37% Other Institutional Investors
49.14% Public Companies and
Individual Investors
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $58.93 and its highest was $95.25 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $43.88B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 24, 2025 which is in 76 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 23, 2025. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.044.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.62.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 585,755,500 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.64 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went up 6.628%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
---
Edwards Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.25 (6.94% Upside)
$80.25 (6.94% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $873.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.95%
12-Months-Change
Fundamentals
Return on Equity
16.73%
Trailing 12-Months
Asset Growth
39.43%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
---
EW Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and strategic advancements, such as significant revenue growth and successful product approvals. However, challenges in the Japan market and anticipated financial impacts from tariffs and acquisitions present potential hurdles.Read More>---
EW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$80.25
▲(6.94% Upside)
Technical Analysis
---